Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity

Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity

Source: 
Stat
snippet: 

The Food and Drug Administration has halted a clinical trial involving a Duchenne muscular dystrophy gene therapy from Solid Biosciences (SLDB) after a patient suffered serious kidney and blood-related injuries, the company said Tuesday.